ArticleJournal of immunology (Baltimore, Md. : 1950)2004
Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function.
Article in Journal of immunology (Baltimore, Md. : 1950), 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 141 citations in OpenAlex.
- Immuno-informatics voyage through molecular mimicry of Heat Shock Proteins: Potential IBD immunopathogenesis.PloS one · 2025Article
- Characterization of the effect of histone deacetylation inhibitors on CD8Journal of translational medicine · 2022Article
- Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.Vaccines · 2022Review
- A new antisarcoma strategy: multisubtype heat shock protein/peptide immunotherapy combined with PD-L1 immunological checkpoint inhibitors.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- The HSP Immune Network in Cancer.Frontiers in immunology · 2021Review
- Immunogenic Cell Death: A Step Ahead of Autophagy in Cancer Therapy.Journal of cancer immunology · 2021Article
- Extracellular gp96 is a crucial mediator for driving immune hyperactivation and liver damage.Scientific reports · 2020Article
- Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.Cancers · 2020Review
- Heat Shock Proteins 90 kDa: Immunomodulators and Adjuvants in Vaccine Design Against Infectious Diseases.Frontiers in bioengineering and biotechnology · 2020Review
- Immunogenic Apoptosis as a Novel Tool for Anticancer Vaccine Development.International journal of molecular sciences · 2018Review
- Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation.World journal of gastroenterology · 2017Article
- Article
- Targeting Hsp70: A possible therapy for cancer.Cancer letters · 2016Review
- Heat shock proteins (HSPs) in the homeostasis of regulatory T cells (Tregs).Central-European journal of immunology · 2016Review
- Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94.Current topics in medicinal chemistry · 2016Review
- Malaria DNA vaccine gp96NTD-CSP elicits both CSP-specific antibody and CD8(+) T cell response.Parasitology research · 2015Article
- Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer.Frontiers in immunology · 2015Review
- Identification of pancreatic cancer-associated tumor antigen from HSP-enriched tumor lysate-pulsed human dendritic cells.Yonsei medical journal · 2014Article
- Secreted heat shock protein gp96-Ig: next-generation vaccines for cancer and infectious diseases.Immunologic research · 2013Review
- Immunogenic cell death: can it be exploited in PhotoDynamic Therapy for cancer?BioMed research international · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The ability of mature T lymphocytes to develop effector capacity after encounter with cognate Ag is generally dependent upon inflammatory signals associated with infection that induce dendritic cell activation/maturation. These inflammatory signals can derive directly from pathogens or can be expressed by host cells in response to infection. Heat shock proteins (HSPs) are a class of host-derived inflammatory mediators that perform the dual function of both chaperoning MHC class I-restricted epitopes into the cross-presentation pathway of DCs and inducing the activation/maturation of these DCs to allow priming of cognate CD8(+) T cell effector responses. Although the ability of HSPs to elicit effector CD8 cell responses has been well established, their potential to prime CD4 cell effector responses has been relatively unexplored. In the current study we compared the ability of the endoplasmic reticulum-resident HSP gp96 to prime CD4 vs CD8 cells using TCR transgenic adoptive transfer systems and soluble gp96-peptide complexes. As expected, gp96 facilitated the cross-presentation of a class I-restricted peptide and priming of effector function in cognate CD8 cells. Interestingly, gp96 also facilitated the in vivo presentation of a class II-restricted peptide; however, the resulting CD4 cell response did not involve the development of effector function. Taken together, these data suggest that gp96 is an inflammatory mediator that selectively primes CD8 cell effector function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.